Jiaoyang Jiang

Dr. Jiaoyang Jiang

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 March 2017 in Nature Structural & Molecular Biology
Verified
Journal Article
Closed access
PDF file
BLBaobin Li
Baobin Li
HLHao Li
Hao Li
LLLei Lu
Lei Lu
JJJiaoyang Jiang
Jiaoyang Jiang

1 June 2019 in Current Opinion in Structural Biology
Verified
Journal Article
Closed access
CJCassandra M Joiner
Cassandra M Joiner
HLHao Li
Hao Li
JJJiaoyang Jiang
Jiaoyang Jiang
SWSuzanne Walker
Suzanne Walker

22 September 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
BLBaobin Li
Baobin Li
HLHao Li
Hao Li
CHChia-Wei Hu
Chia-Wei Hu
JJJiaoyang Jiang
Jiaoyang Jiang
The O-linked β-N-acetyl glucosamine (O-GlcNAc) modification dynamically regulates the functions of numerous proteins. A single human enzyme O-linked β-N-acetyl glucosaminase (O-GlcNAcase or OGA) hydrolyzes this modification. To date, it remains largely unknown how OGA recognizes various substrates. Here we report the structures of OGA in complex with each of four distinct glycopeptide substrates that contain a single O-GlcNAc modification on a serine or threonine residue. Intriguingly, these glycopeptides bind in a bidirectional yet conserved conformation within the substrate-binding cleft of OGA. This study provides fundamental insights into a general principle that confers the substrate binding adaptability and specificity to OGA in O-GlcNAc regulation.

9 February 2016 in Biochemistry
Verified
Journal Article
Closed access
LLLei Lu
Lei Lu
DFDacheng Fan
Dacheng Fan
CHChia-Wei Hu
Chia-Wei Hu
MWMatthew Worth
Matthew Worth
ZMZhi-Xiong Ma
Zhi-Xiong Ma
JJJiaoyang Jiang
Jiaoyang Jiang

12 November 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
XDXingchen Dong
Xingchen Dong
FSFei Sun
Fei Sun
HSHenry Secaira-Morocho
Henry Secaira-Morocho
AHAlisa Hui
Alisa Hui
KWKe Wang
Ke Wang
TFTing Fu
Ting Fu
The gut microbiota has a significant impact on the development and function of intestinal epithelial cells (IECs) by modifying bile acid (BA) metabolites. Recently, specific gut microbiome-derived BAs, such as 7-oxo-deoxycholic acid (7-oxo-DCA) and isodeoxycholic acid (isoDCA), have been identified to be shifted inversely in colitis and hepatic liver diseases. Although the responsible gut microbes have been identified, metabolites’ effects on IECs remain largely unclear. We found that although high-fat diet treatment in mice elevated both 7-oxo-DCA and isoDCA levels, during intestinal tumorigenesis, 7-oxo-DCA levels rise while isoDCA levels decrease. Interestingly, 7-oxo-DCA promotes cancer cell growth, while isoDCA suppresses it. Moreover, 7-oxo-DCA promotes whereas isoDCA inhibits the proliferation of intestinal stem cells in organoids derived from WT and APC Min/+ mice, as well as in patient-derived colon cancer organoids. The APC Min/+ mice administered with 7-oxo-DCA heightened gut permeability and increased tumor burden, whereas isoDCA protected gut barrier and reduced tumor loads. Both BAs reshape the BA pool and shifted gut microbiome. Mechanistically, we identified 7-oxo-DCA as a natural antagonist of Farnesoid X Receptor (FXR) to downregulate FXR signaling, as opposed to isoDCA, which is a potent FXR agonist to upregulate FXR signaling. In conclusion, we unveiled the opposing roles of 7-oxo-DCA and isoDCA to promote or inhibit intestinal tumorigenesis, respectively. Manipulating the BA–FXR axis during tumor initiation and progression holds great promise for developing innovative diagnostic and therapeutic approaches for the treatment of colorectal cancer.

5 January 2017 in ACS Chemical Biology
Verified
Journal Article
Closed access
MWMatthew Worth
Matthew Worth
HLHao Li
Hao Li
JJJiaoyang Jiang
Jiaoyang Jiang